Literature DB >> 23204237

Clonal progression of prostate cancers from Gleason grade 3 to grade 4.

Adam G Sowalsky1, Huihui Ye, Glenn J Bubley, Steven P Balk.   

Abstract

Low-grade prostate cancers (Gleason pattern 3, G3) detected on needle biopsies are generally viewed as indolent and suitable for conservative management with only interval repeat biopsies to monitor by watchful waiting. Higher grade tumors eventually emerge in 20% to 30% of these cases, but this process may only reflect incomplete sampling on the initial biopsy, such that it remains unknown whether G3 tumors generally progress to higher grades. In this study, we examined a series of adjacent G3 and Gleason pattern 4 (G4) tumors in radical prostatectomy specimens and found that all were concordant for the TMPRSS2:ERG gene fusion. Using hybrid-capture and deep sequencing in four fusion-positive cases, we found that adjacent laser-capture microdissected G3 and G4 tumors had identical TMPRSS2:ERG fusion breakpoints, confirming their clonal origin. Two of these G3 tumors had deletion of a single PTEN gene that was also deleted in the adjacent G4, while the G4 tumors in two cases had additional PTEN losses. These findings establish that a subset of G3 tumors progress to G4 or emerge from a common precursor. Further, they show that G3 tumors that progress to G4 may have molecular features distinguishing them from G3 tumors that do not progress. Thus, determining the spectrum of these genetic or epigenetic features may allow for the identification of G3 tumors on needle biopsies that are truly indolent versus those that have the potential to progress or that may already be associated with a G4 tumor that was not sampled at the initial biopsy, therefore, requiring more aggressive surveillance or intervention.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23204237      PMCID: PMC3587758          DOI: 10.1158/0008-5472.CAN-12-2799

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Allelic imbalance in the clonal evolution of prostate carcinoma.

Authors:  L Cheng; D G Bostwick; G Li; Q Wang; N Hu; A O Vortmeyer; Z Zhuang
Journal:  Cancer       Date:  1999-05-01       Impact factor: 6.860

2.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

Review 3.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Authors:  Jonathan I Epstein; William C Allsbrook; Mahul B Amin; Lars L Egevad
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

4.  Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases.

Authors:  Rohit Mehra; Bo Han; Scott A Tomlins; Lei Wang; Anjana Menon; Matthew J Wasco; Ronglai Shen; James E Montie; Arul M Chinnaiyan; Rajal B Shah
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

5.  Evidence of independent origin of multiple tumors from patients with prostate cancer.

Authors:  L Cheng; S Y Song; T G Pretlow; F W Abdul-Karim; H J Kung; D V Dawson; W S Park; Y W Moon; M L Tsai; W M Linehan; M R Emmert-Buck; L A Liotta; Z Zhuang
Journal:  J Natl Cancer Inst       Date:  1998-02-04       Impact factor: 13.506

6.  PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.

Authors:  Tamara L Lotan; Bora Gurel; Siobhan Sutcliffe; David Esopi; Wennuan Liu; Jianfeng Xu; Jessica L Hicks; Ben H Park; Elizabeth Humphreys; Alan W Partin; Misop Han; George J Netto; William B Isaacs; Angelo M De Marzo
Journal:  Clin Cancer Res       Date:  2011-08-30       Impact factor: 12.531

7.  Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease.

Authors:  J I Epstein; P C Walsh; H B Carter
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

8.  20-year outcomes following conservative management of clinically localized prostate cancer.

Authors:  Peter C Albertsen; James A Hanley; Judith Fine
Journal:  JAMA       Date:  2005-05-04       Impact factor: 56.272

9.  Precise microdissection of human prostate cancers reveals genotypic heterogeneity.

Authors:  C A Macintosh; M Stower; N Reid; N J Maitland
Journal:  Cancer Res       Date:  1998-01-01       Impact factor: 12.701

10.  TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.

Authors:  Marc Barry; Sven Perner; Francesca Demichelis; Mark A Rubin
Journal:  Urology       Date:  2007-10       Impact factor: 2.649

View more
  46 in total

Review 1.  Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.

Authors:  Andrea K Miyahira; Joshua M Lang; Robert B Den; Isla P Garraway; Tamara L Lotan; Ashley E Ross; Tanya Stoyanova; Steve Y Cho; Jonathan W Simons; Kenneth J Pienta; Howard R Soule
Journal:  Prostate       Date:  2015-10-19       Impact factor: 4.104

2.  A molecular signature predictive of indolent prostate cancer.

Authors:  Shazia Irshad; Mukesh Bansal; Mireia Castillo-Martin; Tian Zheng; Alvaro Aytes; Sven Wenske; Clémentine Le Magnen; Paolo Guarnieri; Pavel Sumazin; Mitchell C Benson; Michael M Shen; Andrea Califano; Cory Abate-Shen
Journal:  Sci Transl Med       Date:  2013-09-11       Impact factor: 17.956

Review 3.  Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.

Authors:  Christopher J Logothetis; Gary E Gallick; Sankar N Maity; Jeri Kim; Ana Aparicio; Eleni Efstathiou; Sue-Hwa Lin
Journal:  Cancer Discov       Date:  2013-06-28       Impact factor: 39.397

Review 4.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

5.  Mutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma.

Authors:  Sean J Gerrin; Adam G Sowalsky; Steven P Balk; Huihui Ye
Journal:  Prostate       Date:  2016-06-08       Impact factor: 4.104

Review 6.  Molecular correlates of intermediate- and high-risk localized prostate cancer.

Authors:  Huihui Ye; Adam G Sowalsky
Journal:  Urol Oncol       Date:  2018-03-02       Impact factor: 3.498

7.  Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.

Authors:  David J VanderWeele; Richard Finney; Kotoe Katayama; Marc Gillard; Gladell Paner; Seiya Imoto; Rui Yamaguchi; David Wheeler; Justin Lack; Maggie Cam; Andrea Pontier; Yen Thi Minh Nguyen; Kazuhiro Maejima; Aya Sasaki-Oku; Kaoru Nakano; Hiroko Tanaka; Donald Vander Griend; Michiaki Kubo; Mark J Ratain; Satoru Miyano; Hidewaki Nakagawa
Journal:  Eur Urol Focus       Date:  2018-02-15

Review 8.  Active surveillance for low-risk prostate cancer.

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2015-04       Impact factor: 3.092

9.  Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.

Authors:  Kanerva Lahdensuo; Andrew Erickson; Irena Saarinen; Heikki Seikkula; Johan Lundin; Mikael Lundin; Stig Nordling; Anna Bützow; Hanna Vasarainen; Peter J Boström; Pekka Taimen; Antti Rannikko; Tuomas Mirtti
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

Review 10.  Defining the threshold for significant versus insignificant prostate cancer.

Authors:  Theo H Van der Kwast; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.